Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 23, pp. 5651-5660
Open Access | Times Cited: 132

Showing 1-25 of 132 citing articles:

DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, et al.
Cancer Discovery (2017) Vol. 7, Iss. 7, pp. 675-693
Open Access | Times Cited: 581
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova, Minh Nguyen, Kristy Shield‐Artin, et al.
Cancer Discovery (2017) Vol. 7, Iss. 9, pp. 984-998
Open Access | Times Cited: 352
Pathogenesis and heterogeneity of ovarian cancer
Paul Kroeger, Ronny Drapkin
Current Opinion in Obstetrics & Gynecology (2016) Vol. 29, Iss. 1, pp. 26-34
Open Access | Times Cited: 284
BRCA1/2 testing: therapeutic implications for breast cancer management
Nadine Tung, Judy E. Garber
British Journal of Cancer (2018) Vol. 119, Iss. 2, pp. 141-152
Open Access | Times Cited: 173
Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain
Bich Phuong Bui, Phuong Linh Nguyen, Kyeong Lee, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6054-6054
Open Access | Times Cited: 80
N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance
Takeshi Fukumoto, Hengrui Zhu, Timothy Nacarelli, et al.
Cancer Research (2019) Vol. 79, Iss. 11, pp. 2812-2820
Open Access | Times Cited: 145
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Akihiro Ohmoto, Shinichi Yachida
OncoTargets and Therapy (2017) Vol. Volume 10, pp. 5195-5208
Open Access | Times Cited: 125
The role of biomarkers in the management of epithelial ovarian cancer
Wei-Lei Yang, Zhen Lü, Robert C. Bast
Expert Review of Molecular Diagnostics (2017) Vol. 17, Iss. 6, pp. 577-591
Open Access | Times Cited: 121
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Anna Minchom, Caterina Aversa, Juanita Lopez
Therapeutic Advances in Medical Oncology (2018) Vol. 10
Open Access | Times Cited: 118
RAD-ical New Insights into RAD51 Regulation
Meghan R. Sullivan, Kara A. Bernstein
Genes (2018) Vol. 9, Iss. 12, pp. 629-629
Open Access | Times Cited: 118
Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
Paul Lesueur, François Chevalier, Jean-Baptiste Austry, et al.
Oncotarget (2017) Vol. 8, Iss. 40, pp. 69105-69124
Open Access | Times Cited: 116
Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies
Pierpaola Davalli, Gaetano Marverti, Angela Lauriola, et al.
Oxidative Medicine and Cellular Longevity (2018) Vol. 2018, Iss. 1
Open Access | Times Cited: 114
Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting
J. Biau, Emmanuel Chautard, Pierre Verrelle, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 107
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Tarra Evans, Ursula A. Matulonis
Therapeutic Advances in Medical Oncology (2017) Vol. 9, Iss. 4, pp. 253-267
Open Access | Times Cited: 97
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
Xian Chen, Kwang-Huei Low, Angela Alexander, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 24, pp. 6594-6610
Open Access | Times Cited: 94
Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy
Wei Zhao, Ying Cong, Hongmei Li, et al.
Natural Product Reports (2020) Vol. 38, Iss. 3, pp. 470-488
Closed Access | Times Cited: 94
Clinical assays for assessment of homologous recombination DNA repair deficiency
Elizabeth H. Stover, Katherine C. Fuh, Panagiotis A. Konstantinopoulos, et al.
Gynecologic Oncology (2020) Vol. 159, Iss. 3, pp. 887-898
Closed Access | Times Cited: 88
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
Negesse Mekonnen, Hobin Yang, Young Kee Shin
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 58
Curcumin delivery and co-delivery based on nanomaterials as an effective approach for cancer therapy
Mehrab Pourmadadi, Parisa Abbasi, Mohammad Mahdi Eshaghi, et al.
Journal of Drug Delivery Science and Technology (2022) Vol. 78, pp. 103982-103982
Closed Access | Times Cited: 45
Progression in immunotherapy for advanced prostate cancer
Hao Liang, Yang Liu, Jiao Guo, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 28
Update on Emerging Therapies for Advanced Colorectal Cancer
Olatunji B. Alese, Christina Wu, William J. Chapin, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 27
Carrier-Free Nano-PROTACs to Amplify Photodynamic Therapy Induced DNA Damage through BRD4 Degradation
Linping Zhao, Xiaona Rao, Rongrong Zheng, et al.
Nano Letters (2023) Vol. 23, Iss. 13, pp. 6193-6201
Closed Access | Times Cited: 26
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
Stéphanie Lheureux, Jeff Bruce, Julia V. Burnier, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 11, pp. 1240-1249
Closed Access | Times Cited: 83
The role of HIF-1α in chemo-/radioresistant tumors
Yu Xia, Lixia Jiang, Tianyu Zhong
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 3003-3011
Open Access | Times Cited: 82
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
Pierre Bady, Sebastian Kurscheid, Mauro Delorenzi, et al.
Acta Neuropathologica (2018) Vol. 135, Iss. 4, pp. 601-615
Open Access | Times Cited: 78
Page 1 - Next Page

Scroll to top